The COVID-19 vaccine rollout over the past few months has left people with plenty of questions, and the latest concerns about Johnson & Johnson’s single-dose vaccine have probably given folks even more.
The background: The Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) released a joint statement on Tuesday morning, recommending a temporary halt in the distribution of Johnson & Johnson’s JNJ, -1.00% COVID-19 vaccine while they examine six severe cases of rare blood clots that have been reported in people who have received the shot. Health officials called for this short-term stoppage out of “an abundance of caution,” they said, emphasizing that these blood clots were “extremely rare,” and have only happened in less than one in a million vaccinated people. Specifically, just six cases of these rare blood clots have been reported among the 6.8 million Americans who have received the J&J single-dose vaccine. But the CDC wants to ensure that healthcare providers are prepared to treat blood clots if they occur. To read the full story.